<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="225934">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140894</url>
  </required_header>
  <id_info>
    <org_study_id>2005_052</org_study_id>
    <nct_id>NCT00140894</nct_id>
  </id_info>
  <brief_title>A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in
      patients with Familial Adenomatous Polyposis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2003</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and average size of rectal polyps</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and average size of duodenal polyps</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients with improved overall colon rating</measure>
  </secondary_outcome>
  <enrollment>62</enrollment>
  <condition>Adenomatous Polyposis Coli</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0966; rofecoxib / Duration of Treatment: 24 weeks</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo / Duration of Treatment: 24 weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females at least 18 years of age with familial adenomatous polyposis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merck Frosst Canada Ltd.</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H3L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <lastchanged_date>November 30, 2006</lastchanged_date>
  <firstreceived_date>August 30, 2005</firstreceived_date>
  <keyword>Osteoarthritis</keyword>
  <keyword>Cancer Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rofecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
